Can a simple drug make Weight-Loss surgery safer for heavier patients?
NCT ID NCT07192640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving tranexamic acid (TXA) through a vein during weight-loss surgery can reduce blood loss in patients with a very high body mass index (BMI over 45). About 128 high-risk adults will receive TXA or a placebo to see if it lowers the need for blood transfusions and prevents complications. The goal is to make bariatric surgery safer for people with obesity and related health issues like diabetes or heart disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 128 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * High-risk patients, with obesity, BMI more than 45, * Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders. Exclusion Criteria: * patients with active thromboembolic disorders. * Patients with preexisting renal dysfunction,
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bleeding are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
King Salman Specialist Hospital, Hail, KSA
Ha'il, 6539307, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI second pair of eyes could speed up finding hidden bleeding
- Can a cold cloth on the neck calm Post-Surgery nausea?
- Can a lidocaine drip cut opioid use during Weight-Loss surgery?
- Can a standard blood thinner match a newer combo for preventing heart attacks?
- Protein and saline mist may cut bleeding risk after tonsil removal
- Can a newer acid blocker outperform standard care for ulcer bleeding?